Shisanye Group (02005) Announces Annual Results with a net profit of approximately HKD 471 million, a 55.6% decrease year-on-year. Final dividend of HKD 0.03 per share.

Stone Pharmaceutical Group (02005) announced its full-year results for the fiscal year ending December 31, 2025. In 2025, under multiple pressures of shrinking demand, policy deepening, and intensified industry competition, the group’s main economic indicators faced unprecedented downward pressure in recent years, undergoing extremely severe tests. In the face of difficulties, the group actively transformed pressure into motivation, adopting an innovative and pragmatic approach to drive the company’s breakthrough progress.

In 2025, the group achieved sales revenue of approximately RMB 3.812 billion, a year-on-year decrease of 27.6%; in Hong Kong dollars, the annual sales revenue was approximately HKD 4.165 billion, a year-on-year decrease of 27.8%; the gross profit margin during the same period was approximately 41.6%, a year-on-year decrease of 8.8 percentage points; the net profit was approximately HKD 471 million, a year-on-year decrease of 55.6%.

The board decided to distribute a final dividend of HKD 0.03 per share to shareholders listed on the company’s shareholder register on May 21, 2026, with a total annual dividend of HKD 0.08 per share, a year-on-year decrease of 54.3%.

Over the past year, the group has continuously improved the market accessibility of its products. In 2025, the group overcame adverse factors and effectively coordinated the approval of new products and market access in various regions, participating in various drug bidding activities including national centralized procurement, provincial alliances, and local tenders in a timely manner. A total of 42 generic names and 52 specifications were approved for market access throughout the year. At the same time, the group participated in thousands of bidding activities for national centralized procurement, provincial and local joint procurement, and medical institutions, especially excelling in the 11th batch of national centralized procurement, the Beijing-Tianjin-Hebei 3+N alliance volume procurement continuation, the large-volume injectable sodium chloride alliance procurement in Sichuan, and the inter-provincial alliance volume linkage procurement for 66 chemical drugs including adenosine phosphoramidate, plus significant advantages in procurement continuation for drugs like diclofenac in the Guangdong alliance, further solidifying the market foundation in key regions and creating conditions for enhancing product accessibility. In addition, the variety of products in the national medical insurance catalog is increasingly rich, with the new national medical insurance catalog for 2025 adding calcium gluconate sodium chloride injection, bringing the total number of products in the group’s national medical insurance catalog to 201.

Massive information and precise interpretation can be found in the Sina Finance APP.